Search results for "MESH: Risk"

showing 10 items of 30 documents

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection

2014

Item does not contain fulltext Cervical artery dissection (CeAD), a mural hematoma in a carotid or vertebral artery, is a major cause of ischemic stroke in young adults although relatively uncommon in the general population (incidence of 2.6/100,000 per year). Minor cervical traumas, infection, migraine and hypertension are putative risk factors, and inverse associations with obesity and hypercholesterolemia are described. No confirmed genetic susceptibility factors have been identified using candidate gene approaches. We performed genome-wide association studies (GWAS) in 1,393 CeAD cases and 14,416 controls. The rs9349379[G] allele (PHACTR1) was associated with lower CeAD risk (odds ratio…

Male[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyMyocardial InfarctionGenome-wide association studyCarotid Artery Internal DissectionGastroenterologyepidemiology [Carotid Artery Internal Dissection]Brain Ischemia0302 clinical medicineMigraine DisorderOdds RatioFinlandVertebral Artery Dissection0303 health scienceseducation.field_of_studyepidemiology [Hypercholesterolemia]MESH: Middle AgedMESH: Polymorphism Single NucleotidePhactr-1 protein humanMESH: Brain IschemiaMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionHumanmedicine.medical_specialtyMigraine DisordersHypercholesterolemiaMESH: Vertebral Artery DissectionLower riskgenetics [Brain Ischemia]ArticleFollow-Up StudieMESH: Carotid Artery Internal Dissection03 medical and health sciencesGeneticSDG 3 - Good Health and Well-beinggenetics [Carotid Artery Internal Dissection]GeneticsGenetic predispositionepidemiology [Brain Ischemia]Humansepidemiology [Vertebral Artery Dissection]PolymorphismeducationAllelesMESH: Humansgenetics [Vertebral Artery Dissection]MESH: AdultOdds ratioMicrofilament Proteinmedicine.diseaseAdult; Brain Ischemia; Carotid Artery Internal Dissection; Female; Finland; Follow-Up Studies; Genetic Pleiotropy; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Hypercholesterolemia; Hypertension; Male; Microfilament Proteins; Middle Aged; Migraine Disorders; Myocardial Infarction; Obesity; Odds Ratio; Risk Factors; Vertebral Artery Dissection; Alleles; Polymorphism Single NucleotideMESH: Genome-Wide Association StudyCarotid ArteryMESH: Female030217 neurology & neurosurgeryepidemiology [Finland]Cervical ArteryVertebral artery dissectionepidemiology [Hypertension]MESH: HypertensionRisk FactorsMESH: Risk FactorsMESH: ObesityStrokeAlleleGeneticsDissectionMESH: FinlandMicrofilament ProteinsMESH: Genetic Predisposition to DiseaseMESH: HypercholesterolemiaGenetic PleiotropySingle NucleotideMiddle AgedMESH: Migraine DisordersDisorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]epidemiology [Myocardial Infarction][INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV]HypertensionFemale[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processingAdultPopulationMESH: Genetic Pleiotropyphysiology [Microfilament Proteins]BiologyPolymorphism Single NucleotideMESH: Microfilament ProteinsInternal medicineddc:570medicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingGenetic Predisposition to DiseaseObesity030304 developmental biologyepidemiology [Obesity]Risk FactorMESH: Alleles[INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV]InternalMESH: Odds RatioMESH: Maleepidemiology [Migraine Disorders]genetics [Microfilament Proteins]Follow-Up StudiesGenome-Wide Association Study
researchProduct

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

2013

International audience; BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyMESH: Intention to Treat AnalysisMESH: Venous Thromboembolism0302 clinical medicineMESH: Aged 80 and overRecurrence030212 general & internal medicineMESH: WarfarinAged 80 and overMESH: AgedMESH: Middle AgedMESH: RiskHazard ratioAtrial fibrillationVenous ThromboembolismGeneral MedicineMESH: Follow-Up StudiesMiddle AgedIntention to Treat Analysis3. Good healthPulmonary embolismMESH: International Normalized RatioMESH: beta-AlanineMESH: Young AdultAnesthesiaFemaleMESH: Hemorrhagemedicine.drugAdultRiskAdolescentHemorrhageLower riskPlaceboDabigatranDabigatran Venous ThromboembolismYoung Adult03 medical and health sciencesmedicineHumansInternational Normalized RatioAgedMESH: AdolescentIntention-to-treat analysisMESH: Humansbusiness.industryWarfarinMESH: Adultmedicine.diseaseMESH: MaleMESH: Recurrencebeta-AlanineBenzimidazolesWarfarinbusinessMESH: BenzimidazolesVenous thromboembolismMESH: FemaleFollow-Up Studies
researchProduct

Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.

2021

International audience; Background: After liver transplantation (LT),de novo malignancies are one of the leading causes of late mortality. The aim of the present retrospective study was to identify the risk factors of de novo malignancies in a large cohort of LT recipients in France, using Fine and Gray competing risks regression analysis.Methods: The study population consisted in 11004 adults transplanted between 2000 and 2013, who had no history of pre-transplant malignancy, except primary liver tumor. A Cox model adapted to the identification of prognostic factors (competitive risks) was used.Results: From the entire cohort, one (or more)de novo malignancy was reported in 1480 L T recipi…

OncologyAdultMalemedicine.medical_specialtyMESH: Liver TransplantationLiver tumormedicine.medical_treatmentLiver transplantationMalignancyPrimary sclerosing cholangitis03 medical and health sciencesLiver disease0302 clinical medicineMESH: Liver NeoplasmsMESH: Risk FactorsRisk FactorsInternal medicinemedicineHumansMESH: IncidenceLung cancerRetrospective StudiesMESH: HumansHepatologybusiness.industryIncidenceLiver NeoplasmsGastroenterologyRetrospective cohort studyMESH: AdultMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCompeting riskmedicine.disease[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MaleLiver Transplantation030220 oncology & carcinogenesisPopulation study030211 gastroenterology & hepatologybusinessLiver transplantationde novomalignanciesClinics and research in hepatology and gastroenterology
researchProduct

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with adv…

2012

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy. Patients and Methods Twenty-nine patients with HER2-positive breast cancer whose d…

OncologyCancer ResearchReceptor ErbB-2MESH: Risk AssessmentMESH: Dose-Response Relationship Drug0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesProspective cohort studyskin and connective tissue diseasespertuzumab; trastuzumab; breast cancerMESH: Treatment OutcomeMESH: Aged0303 health sciencesMESH: Middle AgedMESH: ErythrocytesAge FactorsMESH: Maximum Tolerated DoseMESH: Neoplasm StagingMiddle AgedPrognosis3. Good healthtrastuzumabMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeOncologyTolerabilityMESH: Receptor erbB-2030220 oncology & carcinogenesisMESH: Survival AnalysisDisease Progression[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Disease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaximum Tolerated DoseMESH: Blood TransfusionBreast NeoplasmsMESH: Drug Administration ScheduleAntibodies Monoclonal HumanizedLoading doseMESH: Cell SeparationRisk AssessmentMESH: PrognosisDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesbreast cancerBreast cancerMESH: PrionspertuzumabInternal medicineHumansMESH: Patient SelectionNeoplasm InvasivenessneoplasmsSurvival analysis030304 developmental biologyAgedNeoplasm StagingMESH: Age FactorsMESH: HumansDose-Response Relationship Drugbusiness.industryPatient SelectionMESH: AdultMESH: Neoplasm InvasivenessMESH: Creutzfeldt-Jakob SyndromeTrastuzumabmedicine.diseaseSurvival AnalysisMESH: Prospective StudiesMESH: Antibodies Monoclonal HumanizedMESH: Disease-Free SurvivalbusinessMESH: FemaleProgressive diseaseMESH: Breast NeoplasmsJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.

2013

International audience; Multiple endocrine neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although genotype-phenotype studies have so far failed to identify any statistical correlations, some families harbor recurrent tumor patterns. The function of MENIN is unclear, but has been described through the discovery of its interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to directly alter its regulation abilities. We report on a cohort of MEN1 patients from the Groupe d'étude des Tumeurs Endocrines. Patients with a…

OncologyMaleendocrine system diseasesProto-Oncogene Proteins c-jun[SDV]Life Sciences [q-bio]Diseasemedicine.disease_causeMESH: Protein Structure Tertiary0302 clinical medicineRisk FactorsMESH: Risk FactorsMESH : FemaleGenetics (clinical)MutationGeneral MedicineMESH: Follow-Up StudiesMESH : Risk Factors3. Good health030220 oncology & carcinogenesisCohortMESH : Proto-Oncogene ProteinsFemaleMESH : MutationMESH : Protein Structure TertiaryMESH : Proto-Oncogene Proteins c-junMESH : Multiple Endocrine Neoplasia Type 1Cohort studymedicine.medical_specialtyendocrine systemMESH: MutationGenetic counselingMESH : MaleMESH: Multiple Endocrine Neoplasia Type 1030209 endocrinology & metabolismBiology03 medical and health sciencesInternal medicineProto-Oncogene ProteinsGeneticsmedicineMultiple Endocrine Neoplasia Type 1HumansMEN1FamilyMolecular BiologyMESH: FamilyMESH: HumansMESH: Proto-Oncogene Proteins c-jun[ SDV ] Life Sciences [q-bio]Proportional hazards modelMESH : HumansCancerMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleProtein Structure TertiaryMESH: Proto-Oncogene ProteinsMutationCancer researchMESH : FamilyMESH: FemaleFollow-Up Studies
researchProduct

Risk-benefit in food safety and nutrition - outcome of the 2019 Parma Summer School

2021

Risk-benefit assessment is the comparison of the risk of a situation to its related benefits, i.e. a comparison of scenarios estimating the overall health impact. The risk–benefit analysis paradigm mirrors the classical risk analysis one: risk–benefit assessment goes hand-in-hand with risk–benefit management and risk–benefit communication. The various health effects associated with food consumption, together with the increasing demand for advice on healthy and safe diets, have led to the development of different research disciplines in food safety and nutrition. In this sense, there is a clear need for a holistic approach, including and comparing all of the relevant health risks and benefit…

Risk analysisFood SafetyMESH: Schools030309 nutrition & dieteticsRisk-BenefitAs isNutritional StatusEFSAMESH: Food SafetyMESH: Risk AssessmentOutcome (game theory)Risk Assessment03 medical and health sciences0404 agricultural biotechnologyRisks and benefitsSettore CHIM/10 - CHIMICA DEGLI ALIMENTINutrition0303 health sciencesSchoolsbusiness.industry04 agricultural and veterinary sciencesTiered approachFood safetyMESH: Nutritional Status040401 food scienceComposição dos AlimentosSegurança AlimentarRisk analysis (engineering)FoodParma Summer SchoolAvaliação do RiscoPsychologybusinessRisk assessment[SDV.AEN]Life Sciences [q-bio]/Food and NutritionCommon currencyMESH: FoodFood Science
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct